USA

News

Magtrace - FDA approved

Breast Cancer Device Receives FDA Approval

Wednesday, 1 August, 2018

Endomag, the surgical guidance company, announced that it has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for Magtrace, the first non-radioactive, dual-tracer for lymphatic mapping in patients with breast cancer undergoing a mastectomy. Magtrace is a liquid...

Endomag team photograph - July 2018

Endomag raises $10 million (£8m) Series C funding led by Draper Esprit to establish a new standard of breast cancer care

Monday, 23 July, 2018

Surgical guidance company, Endomag, today announces a raise of $10 million (£8m) Series C funding, led by Draper Esprit. This investment brings total funding for Endomag to over $22 million (£17m) and will enable the company to significantly expand its capabilities, with the aim of treating more...

Endomag wins Queen's Award

Saturday, 21 April, 2018

Endomag announced today that it has received the Queen’s Award for Enterprise in Innovation for 2018. The Award recognises the Company’s efforts in developing novel surgical tools for more accurate removal of breast cancer.

Endomag has developed a minimally invasive surgical guidance...

University Hospitals System Widens Use of Magseed Marker

Tuesday, 13 March, 2018

Endomag announced today that University Hospitals (UH), one of the leading healthcare systems in the US, providing high-quality, patient-centred cancer care at locations throughout Northeast Ohio, has expanded the use of its Magseed® marker technology at more sites within the UH system. Magseed...

World First for Magseed

Thursday, 22 February, 2018

Endomag announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to extend the indication of its Magseed® magnetic marker to include both the marking of soft tissue and long-term implantation. The Magseed marker has already been used in thousands of...

Endomag

Please select if you are based outside the U.S.A.

Choose

Endomag US

Please select if you are based in the U.S.A.

Choose